Literature DB >> 28694293

The Trophic Life Cycle Stage of the Opportunistic Fungal Pathogen Pneumocystis murina Hinders the Ability of Dendritic Cells To Stimulate CD4+ T Cell Responses.

Heather M Evans1, Andrew Simpson1, Shu Shen2, Arnold J Stromberg2, Carol L Pickett1, Beth A Garvy3,4.   

Abstract

The life cycle of the opportunistic fungal pathogen Pneumocystis murina consists of a trophic stage and an ascus-like cystic stage. Infection with the cyst stage induces proinflammatory immune responses, while trophic forms suppress the cytokine response to multiple pathogen-associated molecular patterns (PAMPs), including β-glucan. A targeted gene expression assay was used to evaluate the dendritic cell response following stimulation with trophic forms alone, with a normal mixture of trophic forms and cysts, or with β-glucan. We demonstrate that stimulation with trophic forms downregulated the expression of multiple genes normally associated with the response to infection, including genes encoding transcription factors. Trophic forms also suppressed the expression of genes related to antigen processing and presentation, including the gene encoding the major histocompatibility complex (MHC) class II transactivator, CIITA. Stimulation of dendritic cells with trophic forms, but not a mixture of trophic forms and cysts, reduced the expression of MHC class II and the costimulatory molecule CD40 on the surface of the cells. These defects in the expression of MHC class II and costimulatory molecules corresponded with a reduced capacity for trophic form-loaded dendritic cells to stimulate CD4+ T cell proliferation and polarization. These data are consistent with the delayed innate and adaptive responses previously observed in immunocompetent mice inoculated with trophic forms compared to responses in mice inoculated with a mixture of trophic forms and cysts. We propose that trophic forms broadly inhibit the ability of dendritic cells to fulfill their role as antigen-presenting cells.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  T cells; cytokines; dendritic cells; fungal infection; lung defense; pneumocystis

Mesh:

Substances:

Year:  2017        PMID: 28694293      PMCID: PMC5607401          DOI: 10.1128/IAI.00396-17

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  37 in total

Review 1.  Immunity to Candida albicans: Th1, Th2 cells and beyond.

Authors:  L Romani
Journal:  Curr Opin Microbiol       Date:  1999-08       Impact factor: 7.934

2.  Murine CD4+ T lymphocyte subsets and host defense against Pneumocystis carinii.

Authors:  J E Shellito; C Tate; S Ruan; J Kolls
Journal:  J Infect Dis       Date:  2000-05-31       Impact factor: 5.226

3.  Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS.

Authors:  A H Limper; K P Offord; T F Smith; W J Martin
Journal:  Am Rev Respir Dis       Date:  1989-11

4.  The adjuvant activity of CpG DNA requires T-bet expression in dendritic cells.

Authors:  Geanncarlo Lugo-Villarino; Shu-Ichi Ito; Dennis M Klinman; Laurie H Glimcher
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-31       Impact factor: 11.205

5.  Choosing and preparing antigen-presenting cells.

Authors:  Clifford V Harding; David Canaday; Lakshmi Ramachandra
Journal:  Curr Protoc Immunol       Date:  2010-02

Review 6.  The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting.

Authors:  Miriam Merad; Priyanka Sathe; Julie Helft; Jennifer Miller; Arthur Mortha
Journal:  Annu Rev Immunol       Date:  2013       Impact factor: 28.527

7.  Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses.

Authors:  B A Garvy; J A Wiley; F Gigliotti; A G Harmsen
Journal:  Infect Immun       Date:  1997-12       Impact factor: 3.441

8.  Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560.

Authors:  K H Nollstadt; M A Powles; H Fujioka; M Aikawa; D M Schmatz
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

9.  Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice.

Authors:  A G Harmsen; M Stankiewicz
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

10.  IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses.

Authors:  Andreas Schlitzer; Naomi McGovern; Pearline Teo; Teresa Zelante; Koji Atarashi; Donovan Low; Adrian W S Ho; Peter See; Amanda Shin; Pavandip Singh Wasan; Guillaume Hoeffel; Benoit Malleret; Alexander Heiseke; Samantha Chew; Laura Jardine; Harriet A Purvis; Catharien M U Hilkens; John Tam; Michael Poidinger; E Richard Stanley; Anne B Krug; Laurent Renia; Baalasubramanian Sivasankar; Lai Guan Ng; Matthew Collin; Paola Ricciardi-Castagnoli; Kenya Honda; Muzlifah Haniffa; Florent Ginhoux
Journal:  Immunity       Date:  2013-05-23       Impact factor: 43.474

View more
  6 in total

1.  Pneumocystis carinii Major Surface Glycoprotein Dampens Macrophage Inflammatory Responses to Fungal β-Glucan.

Authors:  Theodore J Kottom; Deanne M Hebrink; Eva M Carmona; Andrew H Limper
Journal:  J Infect Dis       Date:  2020-09-01       Impact factor: 5.226

Review 2.  New advances in understanding the host immune response to Pneumocystis.

Authors:  J Claire Hoving; Jay K Kolls
Journal:  Curr Opin Microbiol       Date:  2017-11-12       Impact factor: 7.934

3.  First case of low-dose umbilical cord blood therapy for pediatric acute respiratory distress syndrome induced by Pneumocystis carinii pneumonia.

Authors:  Shuang Liu; Huili Shen; Siyuan Huang; Rong Liu; Dong Qu
Journal:  Eur J Med Res       Date:  2021-08-28       Impact factor: 2.175

4.  Targeting CARD9 with Small-Molecule Therapeutics Inhibits Innate Immune Signaling and Inflammatory Response to Pneumocystis carinii β-Glucans.

Authors:  Theodore J Kottom; Eva M Carmona; Andrew H Limper
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

5.  Preclinical and Toxicology Studies of BRD5529, a Selective Inhibitor of CARD9.

Authors:  Theodore J Kottom; Kyle Schaefbauer; Eva M Carmona; Eunhee S Yi; Andrew H Limper
Journal:  Drugs R D       Date:  2022-04-29

6.  Survey of the Transcription Factor Responses of Mouse Lung Alveolar Macrophages to Pneumocystis murina.

Authors:  Theodore J Kottom; Kyle Schaefbauer; Eva M Carmona; Andrew H Limper
Journal:  Pathogens       Date:  2021-05-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.